Mulmit

GT Biopharma, Inc.GT Biopharma, Inc.

GTBP Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2020-12-310-6,764,000-28,296,000
2019-12-31016,056,000-38,647,000

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2025-09-04URBAN ALAN LOUISChief Financial Officer50,000
2025-09-04URBAN ALAN LOUISChief Financial Officer50,000
2025-09-04Mun-Gavin David C.31,250
2025-09-04Kramer Hilary31,250
2025-09-04CASAMENTO CHARLES J62,500
2025-09-04Breen Michael MartinCEO and Director100,000
2025-09-04Breen Michael MartinCEO and Director100,000
2025-09-04Breen Michael MartinCEO and Director100,000
2024-10-17URBAN ALAN LOUISChief Financial Officer23,335
2023-08-11Breen Michael MartinExecutive Chairman/Interim CEO200,000
2023-08-11Ohri ManuCFO & Secretary200,000
2023-08-11Ohri ManuCFO & Secretary200,000

8-K events

FiledItems
2026-09-03Material modification to rights of security holders · Amendments to charter or bylaws · Other events · Financial statements and exhibits
2026-08-14Submission of matters to a vote · Financial statements and exhibits
2026-06-12Amendments to charter or bylaws · Financial statements and exhibits
2026-05-22Delisting or listing-standard notice · Financial statements and exhibits
2026-04-07Entry into a material agreement · Financial statements and exhibits
2026-03-02Non-reliance on previously issued financials · Financial statements and exhibits
2025-11-26Delisting or listing-standard notice · Financial statements and exhibits
2025-11-14Results of operations · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…